ALISO VIEJO, Calif., Feb. 14, 2017 -- NVISION Eye Centers—a national leader in providing the finest suite of ophthalmology services for patients including: custom and Topographic LASIK, KAMRA Inlay, cataract surgery and other vision correction procedures—is pleased to announce today the appointment of Sanjeev Ganatra to Vice President of Corporate Development.
“We could not be more pleased to have Sanjeev joining as a senior leader in our organization,” said Tom Tooma, founder of NVISION. “Our team will benefit tremendously from his keen market insights and from his strategic approach to business development. I look forward to Sanjeev leading the pursuit of collaborative partnerships and accelerating our growth.”
Prior to joining NVISION, Sanjeev served on the executive team of VisionCare, Inc., a privately held ophthalmic medical device company, where he focused his efforts on corporate business development and healthcare marketing of the first in class CentraSight™ platform.
Prior to VisionCare, Sanjeev served ophthalmology in multiple commercial roles with ISTA Pharmaceuticals ranging from sales, analytics and marketing management, ultimately launching the BEPREVE® brand and responsible for the $700 million allergy franchise. At the time of ISTA’s acquisition by Bausch & Lomb, ISTA had grown to become the third largest branded prescription eye care business in the US.
“I’m excited to be a part of the NVISION team working to build and expand our network of corporate and provider partners to improve access to vision for all,” says Sanjeev Ganatra. “By being in more communities and broadening our service offerings, our patients can continue to enjoy the great NVISION experience for more of their eye care needs. I look forward to working with the team to further the successes that NVISION and its partners have enjoyed.”
Sanjeev received his MBA from the University of Southern California, and also holds a Bachelor’s degree in molecular biology from the University of California, San Diego.
ABOUT NVISION EYE CENTERS: NVISION Eye Centers is the premier provider of LASIK and cataract surgery in the US, with centers in California, Nevada, Oregon, Arizona and Toronto, Canada. An innovative leader in ophthalmology, NVISION is dedicated to providing the best patient experience through the use of the latest technology and treatment by the most talented and experienced surgeons in the industry. NVISION was founded in 2010 by Tom Tooma, M.D., one of the earliest pioneers of LASIK, who has performed more than 100,000 procedures throughout his esteemed career. With more than 1,900 eye doctors referring their patients and trusting their own eyes to NVISION surgeons, NVISION Eye Centers is the Eye Doctors' #1 Choice®. For more information, visit www.NVISIONCenters.com or call (877) 455-9942.


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



